Completed NA INTERVENTIONAL 3-arm NCT02450799

Corrected VA With Long-Term Follow-Up After AcrySof® Intraocular Lens (IOL) Implantation

Corrected VA With Long-Term Follow-Up After AcrySof® IOL Implantation

Sponsor: Alcon, a Novartis Company

Interventions Acrylic IOL PMMA IOL Silicone IOL

Updated 8 times since 2017 Last updated: Oct 17, 2016 Started: Jun 30, 2015 Primary completion: May 31, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Pseudophakia and is currently completed. Alcon, a Novartis Company leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Jan 2021 — Dec 2022 [monthly]

Completed NA

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed NA
Feb 2017 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alcon, a Novartis Company

Data source: Alcon Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.